Development and Validation of a HPTLC Method to Estimate Dapagliflozin and Vildagliptin along with Bulk and Marketed Formulation

The analytical investigation work illustrates the expansion along with validation of a HPTLC chromatographic technology intended for instantaneous evaluation drugs, Dapagliflozin (DAPA) along with Vildagliptin (VILDA) within pharmaceutical formulation. Utilizing aluminum-backed TLC plates (10 × 10) already coated with 250m layer of silica gel having pore size 60 with fluorescent indicator F254 while in mobile phase and a mobile phase made up of n-Hexane: EthylAcetate: Methanol (3:6:1 v/v/v), the chromatography was execute. By densitometrically scanning plates at 225nm and 243nm with Camag TLC scanner, the drug's quantitative determination was carried out. The linearity with accuracy along with precision with that detection limit and quantitation limit of as well as robustness of established technique approach was every confirmed. By employing an ultraviolet detector with a wavelength of 225 and 243 nm, DAPA and VILDA were quantified using this method respectively. With supplementary peaks at R_f values of 0.44±0.12 and 0.72±0.23 for DAPA and VILDA correspondingly, both drugs demonstrated deterioration.